miR-34a as part of the resistance network in chronic lymphocytic leukemia.

17p (TP53) deletion identifies patients with chronic lymphocytic leukemia (CLL) who are resistant to chemotherapy. The members of the miR-34 family have been discovered to be direct p53 targets and mediate some of the p53-dependent effects. We studied miR-34a and miR-34b/c expression in a large cohort to define their potential role in refractory CLL. While no expression of miR-34b/c could be detected, we found variable expression levels of miR-34a. miR-34a levels were up-regulated after DNA damage in the presence of functional p53, but not in cases with 17p deletion (P < .001). We found a strong correlation of low miR-34a levels with impaired DNA damage response, TP53 mutations (without 17p deletion), and fludarabine-refractory disease (also in the absence of 17p deletion). Up-regulation of miR-34a after irradiation was associated with induction of Bax and p21, but not Puma. CLL cells with reduced miR-34a expression showed increased viability after DNA damage independently of 17p status. Therefore, low expression of miR-34a in CLL is associated with p53 inactivation but also chemotherapy-refractory disease, impaired DNA damage response, and apoptosis resistance irrespective of 17p deletion/TP53 mutation. The elucidation of mechanisms underlying miR-34a regulation and overcoming its role in chemotherapy resistance warrant further study.

[1]  H. Hermeking.  p53 enters the microRNA world. , 2007, Cancer cell.

[2]  M. James,et al.  11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.

[3]  Stephan Wolf,et al.  Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma , 1998, Oncogene.

[4]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[5]  M. Dyer,et al.  A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL , 2008, Leukemia.

[6]  Y. Pekarsky,et al.  The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[7]  V. Tarasov,et al.  Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.

[8]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[9]  T. Stankovic,et al.  Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. , 2004, Blood.

[10]  John C Reed,et al.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Moshe Oren,et al.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.

[12]  T. Tuschl,et al.  Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.

[13]  H. Döhner,et al.  Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[14]  H. Döhner,et al.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[15]  Š. Pospíšilová,et al.  Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment , 2006, Leukemia.

[16]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Chris Sander,et al.  Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. , 2007, Blood.

[18]  Yi Tie,et al.  Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest , 2008, FEBS letters.

[19]  M. Ziepert,et al.  MicroRNA signatures characterize diffuse large B‐cell lymphomas and follicular lymphomas , 2008, British journal of haematology.

[20]  C. Croce,et al.  MicroRNAs and chromosomal abnormalities in cancer cells , 2006, Oncogene.

[21]  Axel Benner,et al.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.

[22]  J Khan,et al.  The MYCN oncogene is a direct target of miR-34a , 2008, Oncogene.

[23]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[25]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[26]  P. Loehrer.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .

[27]  L. Kanz,et al.  Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. , 1998, Seminars in oncology.

[28]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[29]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[30]  H. Döhner,et al.  How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance , 2008, Leukemia.

[31]  M. Zago,et al.  miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[32]  E. Montserrat.  New prognostic markers in CLL. , 2006, Hematology. American Society of Hematology. Education Program.

[33]  A. Pettitt,et al.  Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia , 2004, British journal of haematology.

[34]  T. Stankovic,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD / SCID mice , 2002 .

[35]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[36]  T. Kipps,et al.  Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation , 2005, Leukemia.

[37]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[38]  Lin He,et al.  The guardian's little helper: microRNAs in the p53 tumor suppressor network. , 2007, Cancer research.

[39]  B. Cheson,et al.  Chronic lymphocytic leukemia: staging and prognostic factors. , 1998, Seminars in oncology.

[40]  T. Hamblin.  Prognostic markers in chronic lymphocytic leukaemia. , 2007, Best practice & research. Clinical haematology.

[41]  R. Siebert,et al.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[43]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[44]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[45]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[46]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.